The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Abstract
Castration-resistant prostate cancer (CRPC) is the most aggressive, incurable form of prostate cancer. MDV3100 (enzalutamide), an antagonist of the androgen receptor (AR), was approved for clinical use in men with metastatic CRPC. Although this compound showed clinical efficacy, many initial responders later developed resistance. To uncover relevant resistant mechanisms, we developed a model of spontaneous resistance to MDV3100 in LNCaP prostate cancer cells. Detailed characterization revealed that emergence of an F876L mutation in AR correlated with blunted AR response to MDV3100 and sustained proliferation during treatment. Functional studies confirmed that ARF876L confers an antagonist-to-agonist switch that drives phenotypic resistance. Finally, treatment with distinct antiandrogens or cyclin-dependent kinase (CDK)4/6 inhibitors effectively antagonized ARF876L function. Together, these findings suggest that emergence of F876L may (i) serve as a novel biomarker for prediction of drug sensitivity, (ii) predict a “withdrawal” response to MDV3100, and (iii) be suitably targeted with other antiandrogens or CDK4/6 inhibitors. Significance: We uncovered an F876L agonist-switch mutation in AR that confers genetic and phenotypic resistance to the antiandrogen drug MDV3100. On the basis of this finding, we propose new therapeutic strategies to treat patients with prostate cancer presenting with this AR mutation. Cancer Discov; 3(9); 1030–43. ©2013 AACR. See related commentary by Nelson and Yegnasubramanian, p. 971 This article is highlighted in the In This Issue feature, p. 953
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · cited 1×
“The mechanism by which MDV3100 inhibits AR signaling has been attributed partially to its ability to hinder nuclear translocation of AR (9).”
BackgroundMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., & Miyamoto, M. (2003) · PubMed · Cited by 425
Overcoming mutation-based resistance to antiandrogens with rational drug design
Balbas, M. D., Evans, M. J., Hosfield, D. J., Wongvipat, J., Arora, V. K., Watson, P. A., Chen, Y., Greene, G. L., Shen, Y., & Sawyers, C. L. (2013) · eLife · doi:10.7554/elife.00499 · Cited by 397 · cited 5×
“To overcome this mutation, Balbas and colleagues (16) coupled modeling with focused chemical screens to discover novel antiandrogens that effectively antagonized AR-WT and AR-F876L.”
BackgroundInfluentialTan, J.-A. (1997) · Molecular Endocrinology · doi:10.1210/me.11.4.450 · Cited by 375
Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal Syndrome
Kevin Kelly, W., & Scher, H. I. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)36163-3 · Cited by 349
AR, the cell cycle, and prostate cancer
Balk, S. P., & Knudsen, K. E. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06001 · Cited by 333
Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 259
Self-citationFunctional characterization of mutant androgen receptors from androgen-independent prostate cancer.
Fenton, M. A., Shuster, T. D., Fertig, A., Taplin, M. E., Kolvenbag, G. J. C. M., Bubley, G. J., & Balk, S. P. (1997) · PubMed · Cited by 225
Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S., & Shimazaki, J. (1996) · The Prostate · doi:10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5 · Cited by 208
Small, E. J., & Carroll, P. R. (1994) · Urology · doi:10.1016/0090-4295(94)90092-2 · Cited by 171
Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Mendiratta, P., Mostaghel, E. A., Guinney, J., Tewari, A. K., Porrello, A., Barry, W. T., Nelson, P. S., & Febbo, P. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2882 · Cited by 135
Contribution of Polycomb Homologues Bmi-1 and Mel-18 to Medulloblastoma Pathogenesis
Wiederschain, D., Chen, L., Johnson, B. V., Bettano, K. A., Jackson, D., Taraszka, J. A., Wang, Y., Jones, M. D., Morrissey, M., Deeds, J. D., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02244-06 · Cited by 122
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 119
Defects of DNA mismatch repair in human prostate cancer.
Chen, Y. Q., Wang, J., Fraig, M., Metcalf, J. S., Turner, W. R., Bissada, N., Watson, D. K., & Schweinfest, C. W. (2001) · PubMed · Cited by 116
Molecular basis for the antiandrogen withdrawal syndrome
Miyamoto, H., Rahman, M. M., & Chang, C. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10757 · Cited by 85
Kawata, H., Ishikura, N., Watanabe, M., Nishimoto-Kakiuchi, A., Tsunenari, T., & Aoki, Y. (2010) · The Prostate · doi:10.1002/pros.21107 · Cited by 66
Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
Kim, W. K., & Ryan, C. J. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0188-2 · Cited by 45
Schiewer, M. J., Den, R. B., Hoang, D. T., Augello, M. A., Lawrence, Y. R., Dicker, A. P., & Knudsen, K. E. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0072 · Cited by 39
Antiandrogen withdrawal syndrome with cyproterone acetate
Sella, A., Flex, D., Sulkes, A., & Baniel, J. (1998) · Urology · doi:10.1016/s0090-4295(98)00354-9 · Cited by 26
Peptide Antagonist of the Androgen Receptor
Gao, W. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790963850 · Cited by 11
Rader, J., Hart, L. S., Russell, M. R., Nakazawa, M. S., Belcastro, L. T., Martínez, D., Carpenter, E. L., Kim, S., Parasuraman, S., Caponigro, G., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-2744 · Cited by 4
Self-citation
Cited by
Gao, H., Korn, J. M., Ferretti, S., Monahan, J. E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3954 · Cited by 1,393
Self-citationActivating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Self-citationRebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Mechanisms of resistance in castration-resistant prostate cancer (CRPC).
Chandrasekar, T., Yang, J. C., Gao, A. C., & Evans, C. P. (2015) · PubMed · doi:10.3978/j.issn.2223-4683.2015.05.02 · Cited by 514
Metadata
- Authors
- Korpal, M., Korn, J. M., Gao, X., Rakiec, D. P., Ruddy, D. A., Doshi, S., Yuan, J., Kovats, S. G., Kim, S., Cooke, V. G., Monahan, J. E., Stegmeier, F., Roberts, T. M., Sellers, W. R., Zhou, W., & Zhu, P.
- Venue
- Cancer Discovery
- Published
- 2013-09-01
- Volume
- 3
- Issue
- 9
- Pages
- 1030-1043
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2130189600
- Cited by
- 561
- References
- 29
- FWCI
- 48.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.